Orvatez (Atorvastatin Calcium, Ezetimibe)

Atorvastatin calcium, the active ingredient in Orvatez, is a HMG-CoA reductase inhibitor presented as a tablet for oral use. It lowers cholesterol levels and is used in adults with hypercholesterolemia or cardiovascular risk. GNH USA supplies Orvatez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orvatez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orvatez combines the cholesterol‑lowering actions of atorvastatin and ezetimibe, acting on lipid metabolism pathways. It is indicated for: - Primary hypercholesterolemia: reduces LDL‑C and non‑HDL cholesterol to achieve guideline‑recommended targets. - Mixed hyperlipidemia: improves total cholesterol, triglycerides and HDL‑C levels. - Homozygous familial hypercholesterolemia: provides additional LDL‑C reduction when statin therapy alone is insufficient. - Cardiovascular risk reduction in patients with established atherosclerotic disease or multiple risk factors : con‑  -